ABSI

Absci Corporation NMS · ABSI

$8.24 -0.07 (-0.90%)

Pullback · -1.14σ

+ Compare Open in Sniper

Valuation

Market cap $1.4B

P/E (ttm) —

Forward P/E -13.2

Beta (5y) 2.33

Shares out 169.4M

Div yield —

Profitability & returns

ROE -63.9%

Net margin —

FCF margin -2259.0%

Debt / equity 0.03

Trading information

Last price $8.24

Day range $8.10 – $8.37

52-wk range $2.24 – $12.06

Avg volume 6.0M

RSI (2) 28.3

Trend zone Pullback

52-week range · today's price

$2.24$12.06

Company

Sector Healthcare

Industry Biotechnology

Exchange NMS

Next earnings 2026-08-11

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-…